The Lions Eye Institute (LEI) clinical trials team has rebranded as ‘Lions Vision Trials’ to establish a unique identity that...
Read moreMelbourne-linked biopharmaceutical company Azura Ophthalmics has announced positive results from a Phase 2 clinical trial of its investigational dry eye...
Read moreClinical trials innovator and digital health expert Ms Michelle Gallaher has been appointed the inaugural CEO of Cerulea, a new...
Read moreA $2.9 million funding injection from the Federal Government will support the rollout of a new saliva-based genetic test for...
Read moreApellis Pharmaceuticals has responded to “positive” 24-month data for its pioneering geographic atrophy (GA) therapy published in The Lancet, demonstrating...
Read moreAstellas Pharma has announced positive 24-month topline results from the GATHER2 Phase 3 clinical study of IZERVAY, developed by its...
Read moreNovartis will discontinue development of GT005 gene therapy, a subretinal injection for geographic atrophy (GA), in a blow to the...
Read moreThe US FDA has approved the use of high dose Eylea (aflibercept) for three macular conditions, equating to longer intravitreal...
Read moreMelbourne biotech company muPharma, founded by ophthalmologist Dr Harry Unger and Mr Mark Unger, has developed an investigational device that...
Read moreMuch effort is going into understanding the impact of combined treatments for myopia management, but little is known about the...
Read moreInsight has been the leading industry publication in Australia for more than 40 years. This longevity is largely due to our ability to consistently deliver accurate and independent news relevant to all ophthalmic professionals and their supporting industry.
© 2024 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited
© 2024 All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited